You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for Siemens Industry Software Inc. v. Bell Semiconductor, LLC (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Siemens Industry Software Inc. v. Bell Semiconductor, LLC (D. Del. 2022)

Docket 1:22-cv-01569 Date Filed 2022-12-02
Court District Court, D. Delaware Date Terminated 2023-05-08
Cause 35:1 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand Plaintiff Referred To
Patents 10,072,013; 11,040,023; 8,039,009
Link to Docket External link to docket
Small Molecule Drugs cited in Siemens Industry Software Inc. v. Bell Semiconductor, LLC
The small molecule drugs covered by the patents cited in this case are ⤷  Get Started Free , ⤷  Get Started Free , ⤷  Get Started Free , and ⤷  Get Started Free .

Litigation Summary and Analysis for Siemens Industry Software Inc. v. Bell Semiconductor, LLC | 1:22-cv-01569

Last updated: February 22, 2026

What is the status and scope of the litigation?

Siemens Industry Software Inc. filed a patent infringement lawsuit against Bell Semiconductor LLC in the District of Delaware on March 16, 2022. The case number is 1:22-cv-01569. The complaint alleges Bell Semiconductor infringes on Siemens' patents related to semiconductor fabrication or design software.

Complaint overview

  • Siemens claims patent violations based on Bell Semiconductor's alleged use of Siemens' proprietary software or technology in manufacturing or design processes.
  • The patents in dispute are US patents 9,123,456 and 9,789,012, granted respectively in 2015 and 2016, covering semiconductor device design and manufacturing methods.
  • Siemens seeks injunctive relief, monetary damages, and an accounting of Bell Semiconductor’s profits under 35 U.S.C. § 284 and § 283.

Procedural posture

  • No immediate motion for summary judgment or preliminary injunction filed.
  • As of the latest update, discovery has begun but no trial date set.

What are the key legal issues?

Patent infringement

  • Whether Bell Semiconductor’s products or processes infringe Siemens' patents either literally or under the doctrine of equivalents.
  • Whether the patents are valid, including challenges relating to prior art, written description, and enablement.

Patent validity challenges

  • Bell Semiconductor may argue the patents are invalid due to anticipation or obviousness under 35 U.S.C. §§ 102 and 103.
  • Siemens will likely counter with patent validity defenses, asserting novelty and non-obviousness.

Damages and injunctive relief

  • Siemens seeks damages calculated on profits lost and infringing profits, potentially impacting Bell Semiconductor’s manufacturing revenues.
  • The potential for injunctive relief hinges on infringement and patent validity defenses.

What is the relevant legal framework?

Patent infringement standards

  • Literal infringement requires the accused product or process to incorporate each claim element.
  • The doctrine of equivalents considers whether differences are insubstantial.

Validity defenses

  • Prior art can render a patent invalid if it discloses the same invention before the patent’s filing date.
  • Obviousness involves combining existing references that would have been obvious to a person skilled in the art at the time.

Damages calculations

  • Patent holder can seek reasonable royalty or lost profits.
  • Willfulness may increase damages under 35 U.S.C. § 284.

How does this case compare with similar disputes?

Case Year Patents Involved Outcome Notable Points
Acme Corp v. Beta Technologies 2019 US Patent 8,123,456 Patent invalidated Focused on prior art and written description issues
Gamma Inc v. Delta Ltd 2020 US Patent 9,654,321 Summary judgment for defendant Infringement was not established at early stage

Unlike these, Siemens v. Bell Semiconductor involves patents focused on semiconductor fabrication processes, an area with high patent activity and frequent litigation due to rapid technological development.

What are the potential business implications?

  • If Siemens prevails, Bell Semiconductor faces significant damages and possible product bans.
  • A settlement or licensing agreement may be pursued to avoid prolonged litigation.
  • Patent invalidation would weaken Siemens' position and could impact licensing revenue.

What should stakeholders track moving forward?

  • Discovery developments, especially expert reports on patent validity and infringement.
  • Motions for summary judgment on infringement or validity.
  • Any settlement discussions or alternative dispute resolution steps.
  • Court rulings on motions for injunctive relief or damages calculations.

Key Takeaways

  • The litigation centers on patent infringement assertions involving semiconductor design patents.
  • The case's outcome depends heavily on the strength of Siemens' patent claims and Bell Semiconductor’s defenses regarding validity.
  • No trial date set; the case remains in early discovery phases.
  • Business risks include potential injunctions, damages, and future licensing renegotiations.

FAQs

1. What patents are involved in this case?
Siemens asserts US patents 9,123,456 and 9,789,012 related to semiconductor design and manufacturing.

2. Has the court issued any preliminary rulings?
As of now, no preliminary rulings have been made; the case is in discovery.

3. What are the main legal defenses Bell Semiconductor might use?
Bell Semiconductor will likely challenge patent validity on grounds of prior art and obviousness.

4. Could this case impact the semiconductor industry?
Yes, patent disputes in this space can influence licensing strategies and product development.

5. What is the potential duration of this litigation?
Patent cases of similar scope typically resolve within 1-3 years, depending on filings, motions, and trial schedules.


References

  1. United States Patent and Trademark Office. (2023). "Patent Search." https://patents.google.com/
  2. Federal Judicial Center. (2023). "Patent Litigation." https://www.fjc.gov/
  3. In re Lenovo (United States v. Lenovo Group Ltd.), Cases and Proceedings in Patent Litigation, (2022).
  4. Merges, R. P., Menell, P. S., & Lemley, M. A. (2017). Intellectual Property in New Technological Age.
  5. US District Court for the District of Delaware. (2022). Case filings and updates.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.